Similar articles

• Response to paper by Kelly et al "The opioid receptor pharmacology of GSK1521498 compared to other ligands with different effects on compulsive reward-related behaviors" published in Psychopharmacology 232, 305-314, 2014.

  Wang D, Sadee W. Wang D, et al. Psychopharmacology (Berl). 2015 Apr;232(8):1493-4. doi: 10.1007/s00213-015-3892-3. Epub 2015 Mar 6. Psychopharmacology (Berl). 2015. PMID: 25740344 No abstract available.
• Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption.

  Nathan PJ, Bakker G. Nathan PJ, et al. Psychopharmacology (Berl). 2021 May;238(5):1255-1263. doi: 10.1007/s00213-019-05427-5. Epub 2020 Jan 4. Psychopharmacology (Berl). 2021. PMID: 31900526 Review.
• The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.

  Ripley TL, Sanchez-Roige S, Bullmore ET, Mugnaini M, Maltby K, Miller SR, Wille DR, Nathan P, Stephens DN. Ripley TL, et al. Psychopharmacology (Berl). 2015 Sep;232(18):3431-41. doi: 10.1007/s00213-015-3995-x. Epub 2015 Jul 5. Psychopharmacology (Berl). 2015. PMID: 26141191 Free PMC article.
• Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist.

  Nathan PJ, O'Neill BV, Bush MA, Koch A, Tao WX, Maltby K, Napolitano A, Brooke AC, Skeggs AL, Herman CS, Larkin AL, Ignar DM, Richards DB, Williams PM, Bullmore ET. Nathan PJ, et al. J Clin Pharmacol. 2012 Apr;52(4):464-74. doi: 10.1177/0091270011399577. Epub 2011 May 24. J Clin Pharmacol. 2012. PMID: 21610207 Clinical Trial.
• Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction.

  Koob GF. Koob GF. Psychopharmacology (Berl). 2017 May;234(9-10):1315-1332. doi: 10.1007/s00213-016-4484-6. Epub 2017 Jan 3. Psychopharmacology (Berl). 2017. PMID: 28050629 Review.